Outlook Therapeutics is trading at $0.95 (-10.42%) in pre-market as investors take profits following a significant rally triggered by FDA approval momentum for its wet AMD treatment.
- The stock experienced a surge during the July 27, 2026, after-hours session, and the current decline is characterized as short-term gain locking.
- While broader markets are currently mixed to weaker, the primary driver for the move is a company-specific pullback following the recent regulatory news.
- The price action follows a period of high volatility as the market digests the impact of the approval on the company's ophthalmic portfolio.